Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and Moderna, Inc. (NASDAQ:MRNA) have reached a stipulation in their ongoing patent infringement litigation.
In 2022, Alnylam filed a patent infringement lawsuit against Moderna, claiming it violated a newly obtained patent.
The claim is over mRNA technology Moderna used in developing its COVID-19 vaccine, Alnylam says.
In the lawsuits filed in U.S. District Court in Delaware, Alnylam said its newly granted patent covers the vaccine’s messenger-RNA delivery systems and violates an Alnylam patent on lipid nanoparticle (LNP) technology for delivering genetic material into human cells.
However, after the ...
